Firefly Neuroscience, Inc. (AIFF) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Firefly Neuroscience, Inc. is an AI technology company developing neuroscientific solutions, including the FDA-cleared BNA™ platform and the Evox System. The company operates as a single reportable segment focused on medical devices and software for brain health assessment. A significant corporate development during the period was the acquisition of Evoke Neuroscience, Inc. on April 30, 2025, to expand hardware and software capabilities.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $299,000 | $342,000 | $22,000 |
| Gross Margin | $274,000 (91.6%) | $317,000 (92.7%) | $22,000 (100%) |
| Operating Loss | $(1,634,000) | $(3,699,000) | $(2,350,000) |
| Net Loss | $(1,833,000) | $(14,763,000) | $(2,386,000) |
| Cash and Equivalents (End of Period) | $5,918,000 | $5,918,000 | $358,000 |
| Operating Cash Flow | N/A | $(4,901,000) | $(2,418,000) |
| Financing Cash Flow | N/A | $11,388,000 | $945,000 |
Balance Sheet Highlights (as of June 30, 2025):
- Total Assets: $14,938,000 (up from $4,601,000 at year-end 2024), driven by cash inflows and acquisition-related assets.
- Goodwill: $5,175,000 (recorded from Evoke acquisition).
- Total Liabilities: $2,838,000.
- Shareholders' Equity: $12,100,000 (recovered from a deficit of $(375,000) at year-end 2024 due to capital raises).
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 1,453% year-over-year for the six months ended June 30, 2025. This is primarily attributed to the inclusion of Evoke Neuroscience operations following the April 30 acquisition.
- Net Loss Expansion: The YTD net loss widened significantly to $(14.8) million compared to $(2.4) million in the prior year. This was driven by a non-cash loss of $9.37 million related to the change in fair value of a derivative liability upon the conversion of a convertible promissory note, and a $1.35 million loss on the settlement of that note.
- Operating Expenses: General and Administrative (G&A) expenses increased 149% YTD to $2.96 million, driven by Evoke integration costs, public company compliance, and professional fees. Selling and Marketing expenses decreased 25% due to staff optimization and reduced consultant fees.
- Liquidity Improvement: Cash balances increased from $1.81 million to $5.92 million, funded by $11.4 million in financing activities, including private placements and warrant exercises.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $106.3 million and expects to continue generating losses. Future operations depend on raising additional capital, which is not guaranteed.
- Unusual Non-Cash Items: The YTD net loss includes a $4.41 million "deemed dividend" related to a warrant inducement agreement and significant losses on derivative fair value adjustments ($9.37 million) and debt settlement ($1.35 million). These items do not reflect cash outflows.
- Acquisition Integration: The company is integrating Evoke Neuroscience, which added $251,000 in revenue and $12,000 in net loss for the period from April 30 to June 30, 2025. An earn-out liability of $478,000 was recorded.
- Internal Control Weaknesses: Management identified material weaknesses in internal controls over financial reporting, specifically regarding Information Technology General Controls (ITGCs) and a lack of segregation of duties. A remediation plan is underway.
- Capital Raises: The company completed a March 2025 Units Offering ($1.64 million gross proceeds) and a June 2025 Units Offering ($1.2 million gross proceeds), alongside significant warrant exercises totaling $8.8 million in proceeds.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the $4.9 million operating cash burn in six months and the explicit "going concern" warning.
- Non-GAAP Adjustments: Analyze the core operating performance by excluding the $10.7 million in non-cash losses related to derivatives and debt settlements to understand the true operational trajectory.
- Dilution Impact: Review the significant increase in share count (from ~8.1 million to ~13.3 million) due to debt conversions, acquisitions, and equity raises, and assess the impact on per-share value.
- Acquisition Synergies: Monitor the integration of Evoke Neuroscience to determine if the revenue contribution scales as projected to offset the increased G&A costs.
- Internal Controls: Track the progress of the remediation plan for the identified material weaknesses in ITGCs and segregation of duties.